JOURNAL OF THE LOUISIANA STATE MEDICAL SOCIETY
RESULTS
CT). Long-term follow-up was ascertained by regular clinic visits or contact with the referring physicians. All data were submitted to the CIBMTR (Center for International Blood and Marrow Transplant Research, in Milwaukee, WI).
Overall, 51 patients were treated with autologous stem cell transplantation using the BCE protocol for conditioning (for clinical details see Table 1). The overall survival (OS) and progression-free survival (PFS) are shown in Figure 1 a and b. The risk factors for disease (HL versus NHL), age at transplant, gender and ethnicity were analyzed and showed no significant differences for survival or survival in remission (see Table 2). The prognosis of patients treated with the BCE protocol showed a trend toward improvement in the most recent time period (2010-2015 versus 1998-2009, see Fig. 2). A total of 26 patients died: 12 of relapsed or refractory disease, four of acute or cardiac complications, one patient (more than six years after the initial diagnosis of NHL) died from secondary acute myelogenous leukemia and one patient (14 years after transplant) died in remission from liver cirrhosis. In eight cases the cause of death was not available from the medical records (four of which had been lost to follow-upduring the aftermathof Hurricane Katrina).
Statistical Analysis
Cross tabulation and Chi-square test were used to examine the association between outcomes of interest and baseline characteristics. Log-rank test and Kaplan-Meier curves were
Patient Characterisitics
Variable Age at SCT (years, median) 46 (range 17-68) Gender Male Female Ethnicity African American/Black Caucasian 14 37 27 24 N = 51
Percentage (100%)
NA
52.9 47.1
27.5 72.5
Diagnosis HL NHL (DLBCL, MCL, T-NHL, CTCL) Year of transplant
24 27
47.1 52.9
(21, 4, 1, 1)
1998 - 2003 2004 - 2009 2010 - 2015
49 1 1 7 18 26
96.1 2.0 2.0 13.7 35.3 51.0
Type of transplant
PB BM PB + BM
Figure 1a: Overall survival
Abbreviations: DLBCL diffuse large B cell lymphoma, MCL mantle cell lymphoma, CTCL cutaneous T cell lymphoma, PB peripheral blood, BM bone marrow
Table 1 : Patient Characteristics
used to calculate overall survival and progression-free survival in relation to independent factors of interest. Cox hazard ratio modeling was used to examine time interaction and to calculate a hazard ratio (HR) and 95% confidence interval. Significance levels were set at (p=0.05). SAS (version 9.3, SAS Institute Inc., Cary, NC) was used for statistical analysis.
Figure 1b: Progression-free survival
36 J La State Med Soc VOL 170 MARCH/APRIL 2018
Made with FlippingBook Digital Publishing Software